A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Global Study with an Open-Label Extension to Evaluate the Efficacy and Safety of Intravenous AOC 1044 (delpacibart zotadirsen) for the Treatment of DMD with Gene Mutations Amenable to Exon 44 Skipping (SAFARI44)

Principal Investigator

Prof Laurent Servais

Contact us

Email: childrensresearch@ouh.nhs.uk

IRAS number

1013327